What Should We Focus on in Sepsis Fluid Resuscitation?--A Research Based on Scientometrics and Visual Analysis

Sepsis is a life-threatening condition and a global disease burden.Heterogeneous syndrome is defined as severe organ dysfunction caused by a dysregulated host response to infection,with renewed emphasis on the immune pathophysiology.Researchers worldwide constantly update the diagnostic criteria of sepsis and have introduced concepts such as“sepsis-3”“Surviving Sepsis Campaign(SSC)”“Early Goal-Directed Therapy(EGDT)”,the 3-h and 6-h bundles to an hour-1 bundle[1],“limited ventilation”“the best PEEP[2]”,and“Lung Protective-Ventilation”.Despite all efforts of experimental and clinical research during the last three decades,the ability to positively influence the course and outcome of the syndrome remains limited.     

HEOS宫腔镜下微型剪刀分离术与宫腔镜电切分离术治疗重度宫腔粘连患者的疗效比较

目的：对比HEOS宫腔镜下微型剪刀分离术与宫腔镜电切分离术治疗重度宫腔粘连（IUA）患者的效果。方法：选取2019年1月至2021年3月收治的96例重度IUA患者，进行前瞻性随机平行对照研究，按随机数字表法分成A组和B组各48例。B组接受宫腔镜电切分离术治疗，A组接受HEOS宫腔镜下微型剪刀分离术治疗。对比两组围术期指标、手术效果、术前及术后3个月血清基质金属蛋白酶-9（MMP-9）、转化生长因子-β1（TGF-β1）水平、术后3个月复发率。结果：A组膨宫液吸收量及术中失血量均较B组少，手术时长较B组短（P＜0.05）；A组总有效率93.75%（45/48）较B组77.08%（37/48）高（P＜0.05）；术后3个月A组血清MMP-9水平较B组高，血清TGF-β1水平较B组低（P＜0.05）；术后3个月A组复发率2.08%（1/48）较B组16.67%（8/48）低（P＜0.05）。结论：与宫腔镜电切分离术治疗重度IUA患者相比，应用HEOS宫腔镜下微型剪刀分离术治疗于优化围术期指标、提升手术效果方面更具优势，且更能有效调节血清MMP-9、TGF-β1水平，降低复发率。     

盐酸纳布啡和舒芬太尼在无痛胃十二指肠镜检查中的效果对比

目的比较盐酸纳布啡与舒芬太尼在胃十二指肠镜检查中的镇痛及术后不良反应发生率。方法选择昆明医科大学第二附属医院拟行无痛胃十二指肠镜检查患者60例,分为舒芬太尼(S)组和纳布啡(N)组。S组静脉推注浓度为0.002%舒芬太尼0.075 m L/kg,N组静脉推注浓度为2%纳布啡0.075 m L/kg。给药3 min以后,两组均接受静脉注射异丙酚1.5～2 mg/kg,静推时间大于60 s。观察记录两组入室后安静状态T0时刻(基础值)、 T1时刻(胃镜插入通过食道入口)、 T2时刻(胃镜插入后3 min)、 T3时刻(胃镜通过幽门进入十二指肠)、 T4时刻(检查后睁眼)的重要的生命体征,如平均动脉压(MAP),心率(HR),呼吸频率(RR)和手指血氧饱和度(SpO2);并记录两组患者丙泊酚用量,无痛胃十二指肠镜检查过程中通过托下颌挤压呼吸气囊辅助呼吸或术中体动次数,检查期间和检查后30 min内出现恶心,呕吐,头晕等不良反应和清醒时间。在无痛胃十二指肠检查后和检查结束时5,15和30 min记录VAS评分和Ramsay评分。结果两组在诱导时间,检查时间,麻醉恢复时间和异丙酚用量方面差异无统... 更多     

miRNA93和miRNA192在H3N2亚型SIV病毒复制及宿主抗病毒免疫中的作用

目的 探讨分离于广西猪流感病毒SW/Guangxi/NS2783/2010和SW/Guangxi/NS650/2012跨种属感染人肺腺癌A549细胞的miRNA93和miRNA192对病毒复制及宿主抗病毒免疫的影响。方法 通过测定不同稀释浓度的病毒感染细胞HA滴度值,确定病毒最佳稀释浓度。荧光定量PCR检测病毒感染细胞后miRNA93和miRNA192表达,Western blot检测病毒NP和HA蛋白表达水平;转染miRNA93和miRNA192抑制剂后,重新检测miRNA93、miRNA192、IFN-β及病毒NP、HA蛋白表达水平。结果 不同稀释度病毒感染人A549细胞后HA滴度的结果显示病毒SW2783的最佳稀释度为10^-3,而SW650的HA滴度无明显变化趋势,提示病毒SW2783对人A549细胞具有较好的适应性和感染能力。荧光定量PCR和Western blot结果提示两株病毒感染细胞后病毒NP和HA蛋白表达均先升高后降低,加入miRNA93抑制剂,两株病毒NP和HA蛋白的表达均上调;加入miRNA192抑制剂,病毒SW2783的HA蛋白表达下调（P=2.10×10^-4）,而SW650的HA蛋白表达上调（P=5.45×10^-5）,NP蛋白反而下调（P=0.034）;ELISA结果提示病毒SW2783和SW650感染细胞后炎症因子IFN-β表达水平随感染时间延长而升高。结论 研究表明miRNA93和miRNA192的表达与SIV病毒增殖及宿主抗病毒免疫有关,可作为干预猪流感病毒跨种属感染的新靶点。     

A Network Pharmacology Study of Reduning Injection for the Treatment of Coronavirus Disease-19

Objective: The 2019 novel coronavirus (2019?nCoV) outbreak has escalated into a global pandemic. According to Chinese guidance for coronavirus disease?19 (COVID?19): Prevention, control, diagnosis, and management, Reduning injection can effectively treat, the disease caused by the virus. To identify the active ingredients of Reduning injection and COVID?19 disease?related pathways, we conducted a network pharmacology study. Methods: The Traditional Chinese Medicine Systems Pharmacology database was used to screen the chemical constituents and potential targets of Reduning injection. The gene names were converted to the corresponding protein names using UniProt. GeneCards and OMIM databases were used to select targets related to 2019?nCoV. Using Cytoscape 3.7.2 software platform and STRING database, we constructed drug?common target and target protein protein?protein interaction network diagrams. Rx64 3.6.2 software and Bioconductor biological information software package were used for? Gene Ontology (GO) functional enrichment and KEGG pathway analyses. Results: In Reduning injection, a total of 33 effective chemical components were obtained that were involved in 151 signaling pathways, of which 44 targets were considered therapeutically relevant. Conclusion: Reduning injection can be potentially applied for the treatment of COVID-19 based on the results of our network pharmacology study.     

基于λ Red重组系统敲除鼠伤寒沙门菌yejE基因

目的 采用改良的λ Red同源重组技术，以减毒沙门菌TT-16（ΔclpP TT-1）为前体菌，构建敲除yejE基因的减毒沙门菌TT-54（ΔclpP ΔyejE TT-1），为后续研究yejE基因的功能奠定基础。方法 （1）将重组质粒PKD46导入减毒沙门菌TT-16（ΔclpP TT-1），获得一次重组受体菌TT-51（ΔclpP PKD46 TT-1）；（2）通过PCR扩增获得yejE基因的一次同源重组打靶片段，将其导入TT-51（ΔclpP PKD46 TT-1），利用四环素平板筛选，获得重组菌TT-52（ΔclpP ΔyejE::tetRA TT-1）；（3）将重组质粒PKD46导入重组菌TT-52，获得同源重组受体菌TT-53（ΔclpP ΔyejE::tetRA PKD46 TT-1）；（4）将PCR扩增获得的yejE基因二次同源重组打靶片段导入TT-53（ΔclpP ΔyejE::tetRA PKD46 TT-1），通过四环素敏感平板筛选，获得敲除了yejE基因的减毒沙门菌TT-54（ΔclpP ΔyejE TT-1）。结果 通过两轮（一次和二次）λ Red同源重组，减毒沙门菌TT-16（ΔclpP TT-1）的yejE基因被成功敲除，PCR及测序鉴定结果符合预期。结论 基于模式菌（大肠杆菌）所构建的λ Red同源重组技术完全适用于沙门菌；通过两轮λ Red同源重组，可实现对沙门菌特定靶基因的无痕敲除。     

生活饮用水中CHCl3和CCl4气相色谱方法的改进

目的 改进生活饮用水国家标准中三氯甲烷（CHCl₃）和四氯化碳（CCl₄）的检测方法，提高检测方法的实用性和检测效率。方法 将国家标准检测方法中的小口径毛细管柱改为大口径毛细管柱，调整标准曲线的浓度范围，设置合适的顶空测试条件。结果 大口径的毛细管柱的理论塔板数n=26 629，分离度R=2.47,CHCl₃的回收率94.8%～101.0%、精密度0.30%～1.23%,CCl₄的回收率95.2%～104.3%、精密度1.58%～4.23%。结论 改进后的方法操作简单、保证了充足的样品进样量、处理简便、分离度较高、干扰较少，适用于生活饮用水中CHCl₃和CCl₄的测定。     

Analysis of retinopathy of prematurity screening in Tianjin, China

AIM: To analyze the findings of retinopathy of prematurity (ROP) exam in Tianjin, and study the impact of pulmonary surfactant Curosurf and nasal continuous positive airway pressure (NCPAP) in ROP. METHODS: A multicenter retrospective review. 2894 preterm infants (1592 males, 1302 females) from several hospitals in Tianjin were screened from January 2009 to December 2013. Demographic information, ophthalmic outcomes and possible systemic risk factors were recorded. Gestation age, birth weight, oxygen supplementation, Curosurf and NCPAP were used to estimate risk factors for ROP. RESULTS: ROP was found in 448 eyes of 224 patients (7.7%). Among which, severe ROP developed in 98 eyes of 49 patients (21.9%). There was significant statistical difference in RDS, NCPAP, and Curosurf usage between control and ROP groups (P=0.000). Multiple logistic regression analyses of ROP indicated that lower birth weight, younger gestational age, and oxygen supplementation were the risk factors leading to ROP. As the usage rate of Curosurf and NCPAP increased year by year, the usage of oxygen supplementation gradually decreased, the incidence of ROP was also on the decline. CONCLUSION: Low birth weight, young gestational age and oxygen supplementation are associated with ROP. The use of Curosurf and NCPAP may be the factor that reduces the occurrence of ROP.